Cancer treatment
A phase Ib/IIa clinical study of the investigational anticancer drug, phenoxodiol, in combination with docetaxel for women with recurrent ovarian cancer is set to take place at the Yale University School of Medicine. The study, initiated by Marshall Edwards, Inc. and supported by Sanofi-Aventis and Marshall Edwards, aims to
Cancer treatment
Abraxane, a new treatment for metastatic breast cancer, has shown significant superiority in efficacy and safety compared to traditional Taxol (paclitaxel) in a pivotal phase III clinical trial published in the Journal of Clinical Oncology. The study, which included 454 patients, demonstrated that Abraxane nearly doubled the response rate and
Drugs
Artemis Pharmaceuticals GmbH and the Spanish biotechnology company Center for Applied Molecular Research Salamanca (Cibasa) have announced a worldwide marketing agreement to collaborate on marketing Cibasa's Oncostem technology. This technology is based on cancer stem cell (CSC) research and will be used to discover and develop novel anticancer
Drugs
Scientists at the University of North Carolina at Chapel Hill have identified a molecule called Ack1 that plays a significant role in the aggressive growth of prostate cancer. Ack1, a member of the growth-promoting tyrosine kinase gene family, stimulates tumor formation by signaling prostate cells to eliminate a tumor-suppressor protein.
Drugs
Researchers led by Kelly Hunt, MD, have published preclinical data demonstrating that INGN 241 works synergistically with celecoxib to inhibit the growth and increase apoptosis of breast cancer cells. The study, published in the medical journal Surgery, showed that the combination of INGN 241 and celecoxib resulted in greater than
Drugs
Neuroblastoma is a complex and often unpredictable childhood cancer that affects the peripheral nervous system. A recent study by the Children's Oncology Group, published in the New England Journal of Medicine, identifies genetic defects on chromosomes 1 and 11 as significant risk factors for high-risk neuroblastoma. The research,
Cancer treatment
Accentia Biopharmaceuticals' subsidiary, Biovest International, has introduced a groundbreaking instrument, AutovaxID-C, at the Cancer Research Institute's meeting, opening new avenues in personalized medicine for cancer treatment. This automated hollow fiber cell culture instrument streamlines vaccine production, reducing the risk of cross-contamination and enabling the segregation of patient-specific
Cancer treatment
Recent research from the United States has shown great promise in using tumor-derived glucose-regulated protein 94 (GRP94/gp96) as a tumor vaccine. However, current protein-based approaches often require large quantities of tumor tissue, which may not be feasible. To address this challenge, scientists at Duke University explored the therapeutic efficacy
Drugs
BioWa, Inc. has secured worldwide rights, excluding Asia, to develop and commercialize a monoclonal antibody targeting fibroblast growth factor 8 (FGF8), a potential new treatment for breast, ovarian, and prostate cancers. This agreement grants Kyowa Hakko Kogyo Co., Ltd., BioWa's parent company, an option to develop and commercialize
Drugs
Researchers in Italy, Canada, and the United States have made significant progress in cancer therapy research, exploring innovative approaches to treat metastatic breast cancer, prostate cancer, and breast cancer. Studies suggest that metronomic therapy, modified metronomic combination therapy, and cyclooxygenase-2 (COX-2) inhibitors show promise in reducing healthcare costs, improving efficacy,
Drugs
Celera Genomics, an Applera Corporation business, has made significant progress in its histone deacetylase (HDAC) inhibitor program, presenting three posters at the American Association for Cancer Research International Conference on Molecular Targets and Cancer Therapeutics meeting. The company's scientists reported extensive molecular profiling of CRA-024781, a potent HDAC
Drugs
Researchers led by Intae Lee, PhD, Department of Radiology, University of Pennsylvania, have presented new data on the effectiveness of Onconase (ranpirnase) against non-small cell lung cancer (NSCLC) at the 47th Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO). The study, titled "The Enhanced Efficacy
